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ABSTRACT 
Background 
Previous reviews have identified medium-large group differences in cognitive performance in adults 
with bipolar disorder (BD) compared to healthy peers, but the proportion with clinically relevant 
cognitive impairment has not yet been established. This review aimed to quantify the prevalence of 
cognitive impairment in euthymic adults with BD, and to describe sociodemographic, clinical and 
other factors that are significantly associated with cognitive impairment. 
Methods 
Systematic literature review. The population was euthymic community-dwelling adults with BD, 
aged 18-70 years, and recruited consecutively or randomly. The outcome was cognitive impairment, 
relative to healthy population norms. Electronic databases and reference lists of relevant articles 
were searched, and authors were contacted. Original cross-sectional studies published in peer-
reviewed English-language journals from January 1994 to February 2015 were included. 
Methodological bias and reporting bias were assessed using standard tools. A narrative synthesis is 
presented together with tables and forest plots.  
Results 
Thirty articles were included, of which 15 contributed prevalence data. At the 5
th
 percentile 
impairment threshold, prevalence ranges were: executive function 5.3% to 57.7%; 
attention/working memory 9.6% to 51.9%; speed/reaction time 23.3% to 44.2%; verbal memory 
8.2% to 42.1%; visual memory 11.5% to 32.9%. More severe or longstanding illness and 
antipsychotic medication were associated with greater cognitive impairment. 
Limitations 
The synthesis was limited by heterogeneity in cognitive measures and impairment thresholds, 
precluding meta-analysis. 
Conclusions  
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Cognitive impairment affects a substantial proportion of euthymic adults with BD. Future research 
with more consistent measurement and reporting will facilitate an improved understanding of 
cognitive impairment burden in BD.  
 
Keywords  Bipolar disorder; cognition; neuropsychology; impairment; prevalence 
 
Registration number PROSPERO reference number CRD42015017558 
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INTRODUCTION 
Bipolar disorder (BD) is known to be associated with cognitive impairment, which persists between 
illness episodes and contributes to functional disability. Impairment is typically found on tests of 
attention, working and episodic memory, processing speed and executive function, with significant 
group differences of medium to large effect size compared to healthy comparison groups (Arts et al., 
2008; Bourne et al., 2013; Mann-Wrobel et al., 2011; Robinson et al., 2006). Although such group-
level differences have been consistently reported, the proportion of adults with BD who have 
clinically relevant levels of cognitive impairment has not yet been clearly established. It is likely that 
there is marked within-group variation, ranging from normal performance through to severe multi-
domain impairment. It has been argued that if overall group differences are being driven by a 
subgroup of patients with marked levels of impairment, this serves to obscure the true picture of 
cognitive impairment in the BD population, which in fact may be severe for some and absent for 
many others (Iverson et al., 2011).  
There are a number of reasons why it would be beneficial to establish the prevalence of 
cognitive impairment in the BD population. From a clinical point of view, cognitive impairment is a 
major contributor to the overall burden of disability in mood disorders, and is a target in its own 
right for therapeutic intervention. Service planning would be helped by clearer information about 
numbers and characteristics of those who are likely to need more clinical or social care input to 
manage the disabling effects of cognitive impairment. From a research perspective, shifting our 
focus to identifying subgroups with cognitive impairment will facilitate efforts to understand why 
some people with BD experience significant problems with cognition while others remain 
unimpaired. This, in turn, may help to identify particular risk factors for clinically significant cognitive 
impairment. 
 
Objectives 
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1. To determine the prevalence of cognitive impairment in euthymic adults with a history of 
BD. 
2. To describe sociodemographic, clinical and other factors that are associated with cognitive 
impairment in BD. 
 
Scope of review 
The population of interest was community-dwelling adults with a history of BD (the exposure), who 
were euthymic at the time of assessment. The outcome of interest was cognitive impairment, 
measured using standardised tests; presence or absence of impairment was defined with reference 
to healthy population norms. Since the aim was to determine prevalence, only cross-sectional results 
were considered (cross-sectional studies or baseline results from cohort studies or trials).  
 
MATERIALS AND METHODS 
The review was conducted according to a structured protocol which followed PRISMA-P guidance 
(Moher et al., 2015). The protocol was registered on the PROSPERO database on 16 March 2015 
(reference number CRD42015017558; 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015017558). Reporting is in 
accordance with PRISMA and MOOSE guidelines (Moher et al., 2009; Stroup et al., 2000).  
 
Eligibility criteria 
The following inclusion criteria were applied during the search and screening process: original 
research published in peer-reviewed journals from 1994 onwards (the year that DSM-IV and ICD-10 
diagnostic classifications came into use); articles published in English; studies of community-dwelling 
adults (not hospital in-patients) aged 18 to 70 years inclusive (to minimise the additional 
contribution of age-related cognitive decline); cross-sectional studies or baseline results from cohort 
studies or trials; clinical samples must have been recruited consecutively from clinics or via a method 
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that ensured eligible individuals in the target population had an equal chance of being approached 
(so that prevalence estimates would be based on representative samples); primary diagnosis of BD; 
euthymic at time of assessment; assessed using at least one direct, standardised, objective cognitive 
measure. Articles were excluded if samples were selected on the basis of presence/absence of 
cognitive impairment (known or suspected). 
 
Concepts and definitions 
Bipolar disorder 
History of bipolar disorder type I, II or not otherwise specified, meeting defined criteria (e.g. DSM or 
ICD). 
Euthymia  
Not meeting defined criteria for a depressive or manic episode at time of cognitive assessment; or as 
otherwise defined by the study authors based on an appropriate clinical measure. 
Cognitive impairment  
Evidence of impaired performance on one or more objective cognitive tests. Impairment was 
defined as the fail range on a pass/fail test, or as otherwise defined by the study authors with 
reference to the score distribution of a healthy comparison group (e.g. from published test norms, or 
an appropriate comparison group recruited to the study). Results based on any threshold that was 
less strict than 1 standard deviation (SD) below the comparison mean would not be considered. 
Prevalence 
Assessments must have been conducted at a single time point, yielding a point prevalence estimate 
of cognitive impairment, reported as the proportion of the sample falling below the cut-off for 
impairment. 
Correlates 
Any sociodemographic, clinical or other factor that was reported by the authors to be significantly 
associated with presence or severity of cognitive impairment.  
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Search strategy 
Information sources 
The following electronic databases were searched on 24 February 2015: Web of Science (Thomson 
Reuters), including Science Citation Index Expanded, Social Sciences Citation Index, Arts & 
Humanities Citation Index, Current Contents Connect, Data Citation Index, MEDLINE and SciELO 
Citation Index; PubMed (NCBI), including MEDLINE, PubMed Central and in-process/ahead-of-print 
citations; EBSCOhost (EBSCO), including CINAHL and PsycINFO. Additional articles published up to 
the search date were sought ǀia: the ͚Đited ďǇ͛ fuŶĐtioŶ ǁithiŶ individual electronic records of 
relevant articles; hand searching of reference lists of relevant articles and recent review papers; and 
email contact with authors.  
 
Process for study identification and selection 
A detailed search strategy was developed and tailored for each electronic database. Controlled 
vocabulary and free text variations were used, including synonyms, abbreviations and spelling 
variants. Appendix 1 shows the search strategy as implemented in Web of Science. Search outputs 
were managed using EndNote software. 
Duplicate records were removed, and study titles and/or abstracts were screened for 
relevance by B.C. Screening was carried out with reference to a detailed checklist of eligibility 
criteria; this was piloted by B.C. and J.W. independently against a sample of initial search results, and 
refined as required (see Appendix 2 for the final checklist). The sensitivity of the search strategy was 
checked by testing whether key papers that were known to be relevant were detected by the search. 
Reproducibility was assessed by J.W., who independently ran the search in one electronic database 
(Web of Science) and screened the first 200 titles and/or abstracts for relevance. Agreement was 
93% (100% following consensus discussion). Full text was obtained for all potentially relevant papers 
that remained. These were assessed by B.C. using the eligibility checklist, with J.W. independently 
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assessing the first 100 papers for comparison. Agreement was 95% (100% following consensus 
discussion). Reasons for exclusion were documented. 
 
Data extraction 
A spreadsheet template was used for extracting data from included papers, having been piloted by 
B.C. and J.W. independently. The list of data fields is given in Appendix 3. Data extraction was carried 
out by B.C., following which J.W. compared four randomly-chosen data extraction records against 
the source papers to check for accuracy and completeness; no discrepancies were identified. Where 
authors appeared to have collected data that could be used to report prevalence of impairment, but 
had not reported prevalence explicitly in the paper (e.g. articles only reporting group mean 
differences), the authors were contacted via email to request prevalence results using an 
appropriate cut-off of their choice. 
 
Assessment of risk of bias 
Risk of bias within studies 
Each included study was assessed for risk of bias using a critical appraisal tool for systematic reviews 
addressing questions of prevalence (Munn et al., 2014). Reporting bias was assessed using the 
STROBE checklist for cross-sectional studies (von Elm et al., 2007). B.C. and N.A.G. independently 
rated randomly-chosen articles for comparison, followed by consensus discussion. Initial rating 
concordance was 83-95% across four articles, and 93% when one further article was independently 
assessed following the consensus discussion exercise. Subsequent ratings were made by B.C. only. 
These assessments were considered in the synthesis and discussion, in order to comment on the 
quality of the literature in this field and to aid interpretation of the results. 
 
Risk of bias across studies 
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Funnel plots were generated using the metafunnel package in Stata v13 (College Station, TX: 
StataCorp LP), to allow visual inspection of the relationship between magnitude and precision of 
prevalence estimates. These are scatter plots depicting a measure of study size (e.g. sample size or 
standard error of the effect estimate) on the vertical axis against the study͛s effect estimate on the 
horizontal axis. Larger (more precise) studies are expected to have effect estimates close to the 
centre on the horizontal axis, and smaller studies are expected to have effect estimates scattered 
symmetrically about the centre. Asymmetry in this characteristic inverted funnel shape indicates 
͞sŵall studǇ ďias͟, for eǆaŵple resultiŶg froŵ puďliĐatioŶ ďias (Egger et al., 1997).  
 
Data synthesis 
Where one study population was analysed in two or more eligible articles, the article reporting the 
largest sample was included in the data synthesis. Additional articles were only included if they 
contributed unique relevant information (e.g. additional cognitive measures). A narrative synthesis is 
presented, alongside summary tables of extracted data (Tables 1 to 3 and Supplementary Tables S1 
to S3), and forest plots of impairment prevalence estimates and 95% confidence intervals (CI) by 
cognitive domain (Figures 2 to 5). Forest plots were generated using the metan package in Stata v13 
(College Station, TX: StataCorp LP). Sociodemographic, clinical and other variables that were 
significantly associated with cognitive impairment were summarised, and consistency in these 
findings was compared across studies (Supplementary Figure S4). Only variables that were potential 
risk factors for impairment were included; variables that were viewed as consequences of that 
impairment (e.g. occupational status, instrumental functioning) were not considered, on the basis 
that they are not potential causal, mediating or moderating factors in explaining the association 
between BD status and cognitive impairment. 
 
RESULTS  
Article selection 
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Figure 1 shows a PRISMA flow diagram of the article selection process. Titles and/or abstracts of 
5,412 records were screened for eligibility, followed by full text evaluation of 658 papers. Forty-six 
articles were deemed eligible. The most common reasons for exclusion were lack of evidence of 
consecutive sample recruitment, inclusion of in-patients in study samples, and inclusion of non-
euthymic participants. Examples of acceptable sample recruitment methods in the eligible articles 
were systematic invitation of: consecutively attending eligible patients at out-patient clinics; all 
eligible patients on a database of open records at a specific clinical service; all eligible persons 
identified via national registers during a specific period. Of the 46 eligible articles, 16 were omitted 
from the data synthesis (see list in Appendix 4): 11 reported on overlapping samples without 
contributing relevant additional information, and for a further five, results directly addressing the 
two research questions of this review were unavailable. 
 
Characteristics of included studies 
Key characteristics of the 30 included articles are summarised in Table 1. The majority included BD-I 
samples only (Altshuler et al., 2004; Arslan et al., 2014; Cavanagh et al., 2002; Cheung et al., 2013; 
Doganavsargil-Baysal et al., 2013; Fakhry et al., 2013; Ferrier et al., 1999; Frangou et al., 2005; 
Goswami et al., 2009; Ibrahim et al., 2009; Jamrozinski et al., 2009; Juselius et al., 2009; Kieseppa et 
al., 2005; Lopera-Vasquez et al., 2011; Lopez-Jaramillo et al., 2010; Normala et al., 2010; Osher et al., 
2011; Pirkola et al., 2005). A further eight articles reported on mixed BD samples (Barrera et al., 
2013; Daban et al., 2012; Elshahawi et al., 2011; Martino et al., 2014; Martino et al., 2008; Mur et al., 
2007; Sánchez-Morla et al., 2009; van der Werf-Eldering et al., 2010) and four articles included 
separate BD-I and BD-II samples (Martino et al., 2011a; Martino et al., 2011b; Martino et al., 2011c; 
Sparding et al., 2015). Three articles reported on samples recruited from population registers of twin 
births and hospital discharges (Juselius et al., 2009; Kieseppa et al., 2005; Pirkola et al., 2005) and 
the rest recruited from specialist psychiatry clinics. Definitions of euthymia differed across studies; 
many used the Hamilton Rating Scale for Depression (HRSD) and the Young Mania Rating Scale 
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(YMRS), but score thresholds varied. Most studies excluded participants with major psychiatric, 
neurological or medical comorbidity or learning disability, and many also excluded those with recent 
substance misuse or electroconvulsive therapy.  
Ratings of methodological and reporting bias are shown in Supplementary Figures S1 and S2, 
respectively. Although all studies aimed to recruit representative participants using consecutive or 
random methods, nine of 30 articles included samples which were unrepresentative of the BD 
population with regard to gender balance and two did not report gender composition. Most articles 
did not report numbers of patients initially considered or deemed eligible, or information about 
comparability of eligible patients who did and did not participate; there was evidence of adequate 
coverage of the intended population in only four articles. Sample sizes were generally small, with 
only seven studies having 50 or more per group. All articles reported on objective cognitive 
measures, but 13 did not report sufficient information to allow appraisal of measurement reliability 
(e.g. qualifications and training of assessors; inter-rater reliability data). Most did not report 
adequate consideration of sources of bias or imprecision in their procedures or interpretation.  
 
Prevalence of cognitive impairment 
Prevalence was available for 15 articles, reporting on 16 BD samples. Tables 2 and 3 show 
prevalence results in BD-I only and mixed BD samples, respectively. Characteristics of these samples 
are provided in Supplementary Tables S1 and S2. Prevalence was available for one study with 
separate BD-I and BD-II samples (Supplementary Table S3).  
 Studies applied a variety of impairment thresholds: some were simple pass/fail cut-offs, and 
others were based on score distributions from published test norms or from a healthy comparison 
group. Distribution-based thresholds ranged from 1SD to 2SD below comparison mean, with the 
most common being 1.5SD (approximately 7
th
 percentile), 1.64SD (approximately 5
th
 percentile) and 
2SD (approximately 2
nd
 percentile). At every threshold and on almost all cognitive measures, 
prevalence of impairment in BD samples was higher than in the comparison group. Heterogeneity in 
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prevalence across studies did not clearly relate to study quality/risk of bias. Studies differed in 
whether they used comparison group score distributions or published norms as the reference for 
impairment, but there was no clear relationship between choice of reference and magnitude of 
impairment prevalence. For example, on the same tests at the same thresholds, Mur et al. (2007) 
used published norms and reported lower prevalence estimates than Juselius et al. (2009), who used 
their own comparison group. On the other hand, Cheung et al. (2013) used published norms and 
reported some of the highest prevalence estimates across several cognitive domains. Prevalence of 
impairment did not differ consistently between BD-I only (Table 2) and mixed BD samples (Table 3), 
although direct comparison is difficult owing to the variation in measures and thresholds used. In the 
only study where BD-I and BD-II samples could be directly compared (Sparding et al., 2015) (Table 
S3), prevalence was higher in the BD-I participants on several measures, but there was considerable 
overlap between the two samples.  
Prevalence of cognitive impairment was further considered according to cognitive domain. 
Results within domains are presented graphically using forest plots, but pooled estimates are not 
reported because of the wide variation in cognitive tests used and in cut-offs applied to define 
presence of impairment. The classification of tests by domain was guided by the classifications used 
by the authors of the original articles. Where tests were thought to cross multiple domains, this is 
indicated in Tables 2 and 3. 
 
Executive function, reasoning and social cognition 
Figure 2 shows prevalence of impairment in studies which used a normative distribution-based 
threshold for impairment. Additional score-based threshold results from three studies (Altshuler et 
al., 2004; Barrera et al., 2013; Normala et al., 2010) are reported in Tables 2 and 3. Measures which 
are significantly influenced by performance speed are considered separately from those that are not, 
to minimise the overlap between underlying processing speed ability and instrumental executive 
function. The former category included timed fluency measures, Stroop test, Trailmaking test, and 
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composite scores primarily influenced by these. The latter category included Tower tests, non-time-
dependent aspects of fluency tasks (e.g. category switching accuracy), reasoning tests, Wisconsin 
Card Sorting test, BADS Six Elements task, and composite scores primarily influenced by these.  
Figure 2 shows that impairment prevalence tended to be slightly higher on speed-sensitive 
tasks (panel B) than on those that depend less on speed (panel A), though this pattern was not 
evident in all studies. The estimates did not follow a clear gradient according to the different 
threshold strata: for example, the estimates from Cavanagh et al. (2002) were the same at the 5
th
 
and 2
nd
 percentile levels. This may be a consequence of small sample size, or may indicate that 
impaired individuals were strongly clustered at the extreme low end of the score distribution, such 
that less strict thresholds made little difference to the absolute numbers considered impaired. The 
estimates from Juselius et al. (2009) were somewhat higher than expected in the context of the 
other studies. This may be related to study size and quality, but it should also be noted that this 
study included several twin pairs who were concordant for BD. BD-II-only results are not shown in 
Figure 2, but Supplementary Table S3 indicates that fewer BD-II participants were impaired, in 
comparison with BD-I participants, on most executive function measures in Sparding et al. (2015). 
Only one study provided prevalence data for social cognition tasks (Barrera et al., 2013): in a small 
mixed BD sample (n = 12), prevalence of impairment on emotional and cognitive theory of mind 
measures was higher compared to the healthy comparison sample (Table 3).  
 
Attention and working memory 
Figure 3 shows the prevalence of impairment in five studies (of similar quality) that reported 
attention/working memory measures. Estimates were generally higher than in the healthy 
comparison population, and this was most striking on the CNS-VS complex attention score reported 
by Cheung et al. (2013) and the Mindstreams attention score from Osher et al. (2011). These scores 
are composites of several demanding tasks, more akin to the executive measures presented in 
Figure 2. Additional measures from Normala et al. (2010) are reported in Table 2, showing a slightly 
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elevated percentage of BD participants with reduced forward and backward digit span. The study by 
Sparding et al. (2015) allows comparison between BD-I and BD-II samples on two attention/working 
memory measures, indicating that proportions impaired were similar (Supplementary Table S3). 
 
Speed and reaction time 
Figure 4 shows that prevalence of impairment on speed and reaction time measures was similar 
across different impairment thresholds. However, Daban et al. (2012) reported that 30.2% were 
impaired on the WAIS-III Digit Symbol Coding task at the 5
th
 percentile threshold, whereas Sparding 
et al. (2015) reported 19% impairment prevalence on the same task at the less strict threshold of 
11
th
 percentile. Daban et al. assessed a mixed BD sample but did not report subtypes or illness 
ĐharaĐteristiĐs, ŵakiŶg it diffiĐult to iŶfer reasoŶs for the disparitǇ ǁith “pardiŶg et al.͛s BD-I sample. 
It was also evident from the Sparding et al. study that fewer BD-II participants were impaired on 
these tasks; in the case of WAIS-III Digit-Symbol Coding, the proportion impaired (11%) was in line 
with the normative score distribution (Supplementary Table S3). 
 
Memory 
Figure 5 shows impairment prevalence results for verbal memory (panel A) and visual memory 
(panel B). Additional score-based threshold results from Ibrahim et al. (2009) are shown in Table 2. 
Two studies of similar quality that reported composite verbal and visual measures separately 
(Cheung et al., 2013; Sánchez-Morla et al., 2009) showed contradictory findings regarding relative 
prevalence of impairment: both studies reported that 28.8% were impaired on verbal memory at the 
5
th
 percentile threshold, but proportions impaired on visual memory were 11.5% in Cheung et al. 
(2013) versus 32.9% in Sánchez-Morla et al. (2009). The proportions impaired on overall memory 
composite measures were 43.1% at the 7
th
 percentile threshold (Osher et al., 2011) and 30.8% at the 
5
th
 percentile (Cheung et al., 2013).  
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The California Verbal Learning Test (CVLT) was the most common of the verbal measures, 
used in four studies with different thresholds. Results from Cavanagh et al. (2002) and Altshuler et 
al. (2004) indicated a threshold-related gradient, with fewer participants falling below the stricter 2
nd
 
percentile level for CVLT learning and recall, though not for recognition performance. Sánchez-Morla 
et al. (2009) reported lower impairment prevalence than Cavanagh et al. using the same 5
th
 
percentile threshold for the same CVLT measures (total trials 1 to 5, and long delay recall). This may 
be explained by the larger sample size and mix of BD-I and BD-II participants in the former study. No 
verbal memory results were available for BD-II separately.  
 Visual memory results were available from four studies of similar quality. Three (Mur et al., 
2007; Sánchez-Morla et al., 2009; Sparding et al., 2015) used the Rey Complex Figure Test (RCFT) at 
different impairment thresholds; prevalence on this test was lowest in Sparding et al. (2015) despite 
the less strict threshold and more severe clinical characteristics of their sample. Prevalence of visual 
memory impairment was similar between BD-I and BD-II samples in that study (Supplementary Table 
S3).  
 
Visuospatial function 
Three studies (Osher et al., 2011; Sánchez-Morla et al., 2009; Sparding et al., 2015) reported 
visuospatial measures (Tables 2, 3 and S3). Impairment prevalence was lower for visuospatial tasks 
than for other cognitive domains, though still somewhat higher than would be expected from the 
normative distribution. Prevalence was highest on the WAIS-III Block Design task—reported as 40% 
by Sparding et al. (2015) at the 11
th
 percentile threshold—which may reflect the executive and speed 
components that contribute to success on this task. Prevalence was similarly high among BD-II 
participants on this task (Sparding et al., 2015).  
 
Any domain, multi-domain and global impairment 
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Fakhry et al. (2013) used the Mini-mental State Examination (MMSE), Mental Test Score (MTS) and 
Clock Drawing Test (CDT)—typically used as global measures in dementia settings—to assess BD-I 
participants, grouped by the polarity of their most recent illness episode. Table 2 shows that the 
proportions falling below the impairment cut-off were markedly higher in the group whose most 
recent episode was manic. No BD participant scored below the cut-off on the CDT, however.  
 Osher et al. (2011) reported that 49% of their BD-I sample fell below the 7
th
 percentile 
(1.5SD) on the global cognition measure of the Mindstreams computerised battery. Also in BD-I, 
46.2% of the Cheung et al. (2013) sample were below the 5
th
 percentile on the CNS-VS overall 
measure of neurocognition. Furthermore, 61.5% were at least 1SD below the normative mean on at 
least two CNS-VS index scores, and 40.4% met the stricter criterion of being at least 2SD below the 
normative mean on at least two index scores.  
 Two studies reported overall results from mixed BD samples. Van der Werf-Eldering et al. 
(2010) found that 6 of 46 participants (13%) were at least 2SD above the healthy comparison mean 
(where higher scores indicated worse performance) in at least one cognitive domain. The sample of 
46 was a euthymic sub-group from a larger study, for whom demographic and clinical characteristics 
were not available. It is therefore unclear why the proportion impaired was relatively low in this 
study. Martino et al. (2014) assessed a larger sample (n = 100), and reported that 70% were impaired 
usiŶg ͞soft͟ Đriteria (1.5“D ďeloǁ the normative mean in at least one cognitive domain) and 30% 
ǁere iŵpaired usiŶg ͞hard͟ Đriteria (at least 2SD below the normative mean on at least two 
domains).  
 
Risk of bias across studies 
Supplementary Figure S3 shows funnel plots of the relationship between prevalence estimates and 
their precision (standard error), presented separately by cognitive domain, for studies reporting 
measures at the 5
th
 percentile impairment threshold. Visual inspection suggested a degree of 
asymmetry for measures of verbal memory, and to a lesser extent for speed-sensitive measures 
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(both within the executive domain and on specific tests of speed/reaction time). Relatively fewer 
estimates in the lower left quadrant of these plots may indicate publication bias, or reflect other 
factors such as different sample characteristics or assessment methods in the smaller/less precise 
studies. The small number of independent measures meant it was not possible to apply statistical 
tests of asymmetry. 
 
Factors associated with cognitive impairment 
Twenty-eight articles provided information regarding the association between various 
sociodemographic, clinical or other variables and presence or severity of cognitive impairment. 
Articles were not always clear about which associations had been tested statistically, and they varied 
in the extent to which they adjusted for potential confounders. Supplementary Figure S4 shows an 
overview of the types of variables tested, with significant findings highlighted across studies.  
Associations with demographic variables and premorbid ability were often not tested. In 
some cases this was because key background factors had been frequency-matched in a between-
group study design, or had been adjusted for when calculating standardised cognitive scores. Other 
analyses included these background factors as covariates (e.g. in multiple regression), without 
reporting results for these covariates separately. For the remainder, greater cognitive impairment 
was associated with older age and lower education and premorbid ability in some studies, but others 
reported no significant findings. 
Illness characteristics—such as duration since onset, number of affective episodes and 
hospitalisations, history of psychotic symptoms, and residual depressive or manic symptoms—were 
more frequently investigated. Where significant results were reported, they indicated that more 
severe illness characteristics were associated with worse cognitive function. An exception was 
history of psychotic symptoms, for which one study reported both positive and negative effects. 
Several studies investigated associations with psychotropic medication, with mixed findings. The 
strongest evidence of association was between antipsychotic medication and worse cognition, 
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though some studies reported null findings. By contrast, mood stabilisers (lithium or 
anticonvulsants) were less frequently associated with impairment.  
Although two studies examined history of alcohol/substance use disorder, none investigated 
the relationship between frequency/amount of alcohol or recreational drug consumption and 
cognitive impairment. No study examined associations with smoking or other cardiovascular risk 
factors that may be relevant to cognitive impairment. 
 
DISCUSSION 
Summary of findings 
The aims of this review were to determine the prevalence of cognitive impairment in euthymic 
adults with BD, and to ascertain which clinical, sociodemographic or other factors were associated 
with cognitive impairment in this population. Thirty articles contributed to the findings, of which 15 
provided prevalence. Impairment prevalence was similar between BD-I only and mixed BD samples. 
One study with separate results for BD-I and BD-II participants indicated that impairment was more 
common in those with BD-I, though considerable overlap was apparent. Examination of impairment 
proportions across different cognitive domains indicated wide variation both within and between 
domains. For example, taking the 5
th
 percentile threshold as the reference, impairment prevalence 
ranges were as follows: non-speed-sensitive executive function 5.3% to 57.7%; speed-sensitive 
executive function 10.0% to 36.8%; attention/working memory 9.6% to 51.9%; speed/reaction time 
23.3% to 44.2%; verbal memory 8.2% to 42.1%; visual memory 11.5% to 32.9%. Generally small 
sample sizes resulted in wide CIs for most estimates. A recent review of neuropsychological function 
in BD (Szmulewicz et al., 2015) highlighted impairment prevalence as an issue of particular interest, 
and reported estimates between 30% and 57% from six studies. Four of these studies were not 
eligible for the present review, either because participants were not euthymic or because the 
recruitment method did not meet our criteria. The fact that the lower bounds of the prevalence 
estimates reported in the present review are below the previous estimate of 30% can be understood 
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in light of our exclusion of non-euthymic participants and samples recruited by convenience, either 
of which may bias prevalence estimates upwards.  
There was some evidence that more severe or longstanding illness was associated with 
greater cognitive impairment. Several studies reported an association with antipsychotic medication 
but less so with other types of psychotropic medication; it should be noted, however, that 
medication associations are likely to be confounded by illness severity as well as treatment 
adherence and responsiveness. A previous individual participant data meta-analysis of 2,876 
euthymic patients with BD (Bourne et al., 2013) also reported significant correlations between 
cognitive impairment and some illness severity indices (number of manic episodes and total 
hospitalisations), and reported an association for antipsychotic medication only, but not lithium, 
antidepressants or anticonvulsants.  
 
Limitations of included studies 
Valid prevalence estimates depend on representative samples, but representativeness was 
questionable in many of the studies included here. Although all appear to have used an appropriate 
recruitment method (e.g. consecutive or random sampling), details were scant in published papers 
regarding exact recruitment processes and numbers considered at each stage. Exclusion on the basis 
of comorbidity such as substance misuse was common, but numbers excluded were rarely reported. 
Definitions of euthymia varied; even when these were based on common measures (e.g. HRSD and 
YMRS), cut-off scores differed across studies. Some degree of residual affective symptoms was 
present in most BD samples, but this was not always considered as a confounding factor in analyses. 
A wide range of cognitive tests was used, and even within specific tests, many different scores were 
reported (e.g. CVLT sub-scores). This made direct comparison across studies difficult. The use of 
different thresholds to define cognitive impairment also limited synthesis at the outcome level. Most 
studies focused on the cognitive domains of executive function, memory and attention, with other 
areas of function such as visuospatial ability, language and praxis studied rarely if at all. Articles were 
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sometimes unclear regarding which demographic, clinical or other variables were statistically tested 
against cognitive measures.  
 
Limitations of review 
We aimed to follow best practice in systematic review methodology, but reproducibility of 
screening, data extraction and bias appraisal processes was checked for only a proportion of records. 
Judgements about study eligibility relied solely on information contained in the articles, and authors 
were not contacted to request missing information during the selection process. A large number of 
articles were excluded on the sample recruitment criterion, in some cases because this information 
was not contained in the article; it is possible that some of these did in fact employ an appropriate 
sampling procedure. The requirement for information within the article indicating an acceptable 
procedure meant that several articles included in previous reviews of cognition in BD are not 
included here, including some that reported prevalence estimates. Despite repeated attempts to 
obtain additional prevalence results  from authors of eligible articles, prevalence data were available 
for only 15 articles. In particular, there was little information regarding impairment prevalence in 
BD-II samples. Heterogeneity of cognitive measures and thresholds meant that it was not feasible to 
meta-analyse the prevalence estimates obtained, or to conduct statistical tests of funnel plot 
asymmetry, and so the results are limited to graphical and narrative synthesis only. This was 
organised by cognitive domain, but we acknowledge that many tests make multiple cognitive 
demands across domains. Regarding our second research question, variation in the way that 
correlates were analysed across studies meant it was not possible to comment on the nature of any 
inter-relationships between the potential risk factors reported here. Risk of bias was considered 
carefully, but it should be noted that the appraisal tool used was developed for questions of 
prevalence, whereas many of the studies included here were not originally designed to investigate 
prevalence. The literature search results were restricted to English-language publications only, 
although studies from a wide range of international settings were found.  
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Conclusions and implications 
This review is the first to systematically examine the prevalence of cognitive impairment in euthymic 
bipolar disorder. It complements and extends the findings of previous reviews, which have focused 
on magnitude of between-group differences on cognitive measures. Although group differences are 
important for understanding the nature and extent of cognitive impairment in this population, 
quantifying the number who have clinically relevant cognitive impairment is essential if we wish to 
identify risk factors for a cognitively impaired subtype of euthymic BD, and to target clinical 
resources towards neuropsychological rehabilitation and support for those who need it most. 
Despite the heterogeneity in the present findings, some tentative conclusions can be drawn. 
Cognitive impairment affects patients across the BD spectrum; impairment appears to be more 
common in BD-I but there is considerable overlap with BD-II. It is also evident that even at the lower 
ends of the prevalence ranges reported here, the proportion of patients whose affective illness is in 
remission but who continue to show cognitive impairment substantially exceeds the expected 
proportion in the general population. With BD diagnosis typically being made in early adulthood, this 
means that the excess burden of cognitive impairment will affect this population over several 
decades. There is a great need for effective interventions for cognitive dysfunction in BD, with 
significant potential to reduce adverse impacts on educational, occupational and domestic 
functioning over many years.   
The wide variation in the prevalence estimates reported here calls attention to the need for 
greater consistency across studies. This could be achieved by using internationally recommended 
assessment batteries, such as those based on the MATRICS Consensus Cognitive Battery (Van 
Rheenen and Rossell, 2014; Yatham et al., 2010). Researchers should consider reporting impairment 
prevalence at more than one threshold, to facilitate comparison across studies. There is no single 
consensus threshold to define impairment in clinical practice, since this depends on contextual 
factors such as premorbid ability, but providing results for several relevant levels would maximise 
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value from data gathered. It would also be very useful to provide graphical summaries of score 
distributions, to indicate whether cognitive performance in BD samples (both BD-I and BD-II) 
demonstrates an overall distribution shift compared to healthy comparison groups, or a bimodal 
picture of distinct impaired versus preserved subgroups. Inspection of standardised mean 
differences together with proportions impaired does not permit a full appreciation of these issues. 
This review did not attempt to quantify the proportion of people with BD who are above average on 
cognitive measures, but this is arguably of equal importance in considering the diverse cognitive 
phenotype associated with this disorder. Finally, greater efforts should be made to recruit 
representative samples of adults with BD for cognitive studies. Much of the research in this field is 
carried out with clinic samples recruited by convenience. Only large, representative samples can 
provide an accurate picture of the burden of cognitive dysfunction in adults living with BD, through 
which we can understand the factors that influence risk and resilience. 
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FIGURE TITLES AND LEGENDS 
Figure 1 PRISMA flow diagram showing results of literature search and screening. 
 
Figure 2 Executive function impairment prevalence across different thresholds. 
BADS, Behavioural Assessment of the Dysexecutive Syndrome; BD, bipolar disorder; BD-I, bipolar 
disorder type I; CI, confidence interval; CNS-VS, Central Nervous System Vital Signs computerised 
battery; TMT, Trailmaking Test; WAIS-III, Wechsler Adult Intelligence Scale third edition; WCST, 
Wisconsin Card Sorting Test. 
Results include mixed BD and BD-I samples. Some studies reported results for several cognitive 
scores, and so there is sample overlap across rows. CI estimates are based on standard errors 
calculated as follows: sqrt((prevalence*(100-prevalence))/n). Results are stratified by impairment 
threshold (percentile), in descending order from least to most strict. Panel A shows executive 
measures whose scores do not have a prominent timed/speed contribution, and panel B shows 
executive measures whose scores are influenced by speed.  
 
Figure 3 Attention/working memory impairment prevalence across different thresholds.
 
BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central Nervous 
System Vital Signs computerised battery; CPT, Continuous Performance Test; WAIS-III, Wechsler 
Adult Intelligence Scale third edition. 
Results include mixed BD and BD-I samples. Some studies reported results for several cognitive 
scores, and so there is sample overlap across rows. CI estimates are based on standard errors 
calculated as follows: sqrt((prevalence*(100-prevalence))/n). Results are stratified by impairment 
threshold (percentile), in descending order from least to most strict.  
 
Figure 4 Speed/reaction time impairment prevalence across different thresholds.
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BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central Nervous 
System Vital Signs computerised battery; CPT, Continuous Performance Test; TMT, Trailmaking Test; 
WAIS-III, Wechsler Adult Intelligence Scale third edition. 
Results include mixed BD and BD-I samples. Some studies reported results for several cognitive 
scores, and so there is sample overlap across rows. CI estimates are based on standard errors 
calculated as follows: sqrt((prevalence*(100-prevalence))/n). Results are stratified by impairment 
threshold (percentile), in descending order from least to most strict.  
 
Figure 5 Verbal and visual memory impairment prevalence across different thresholds.
 
BD, bipolar disorder; BD-I, bipolar disorder type I; CI, confidence interval; CNS-VS, Central Nervous 
System Vital Signs computerised battery; CVLT, California Verbal Learning Test; RCFT, Rey Complex 
Figure Test; WAIS-III, Wechsler Adult Intelligence Scale third edition. 
Results include mixed BD and BD-I samples. Some studies reported results for several cognitive 
scores, and so there is sample overlap across rows. CI estimates are based on standard errors 
calculated as follows: sqrt((prevalence*(100-prevalence))/n). Results are stratified by impairment 
threshold (percentile), in descending order from least to most strict. Panel A shows verbal memory 
measures and panel B shows visual memory measures. 
 
Table 1 Characteristics of included articles 
 
Author 
Year 
Country Sample n BD sample type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
Altshuler 
2004  
USA 40 22 BD-I 
DSM-III-R 
HRSD <6 and YMRS <7 for 3 consecutive 
months 
Head injury with LOC >1 hour; learning disability; migraine; liver function 
abnormalities; alcoholic dementia; abuse of alcohol in past 6 months; history of 
cocaine abuse/dependence; diabetes; hypertension; seizure disorder; any other 
neurologic illness; left-handedness; ECT in past 2 years; other current DSM-III-R 
Axis I disorder 
Arslan 
2014  
Turkey 30 32 BD-I 
DSM-IV 
H‘SD <ϳ aŶd MAD‘S <ϭϮ aŶd YM‘S чϭϮ DSM Axis I comorbidities; mental retardation; hearing/visual loss interfering 
with clinical interview; alcohol/substance abuse in past 6 months; any disease 
affecting CNS; head trauma with LOC 
Barrera 
2013  
Argentina 12 12 BD-I or BD-II 
Not stated 
HRSD (17 items) <7 and YMRS <8  Significant medical diseases; neurological disorders; mental deficiency; drug 
abuse 
Cavanagh 
2002  
UK 20 20 BD-I 
DSM-IV 
H‘SD чϳ aŶd MMS чϮ Significant physical or neurological illness; stroke or head trauma; significant 
alcohol and/or drug misuse; ECT in past 6 months; comorbid psychiatric 
disorder; neurodegenerative disorder; learning disability; endocrine 
abnormalities 
Cheung 
2013  
China (Hong 
Kong) 
52 52 BD-I 
ICD-10 and 
DSM-IV 
HRSD (21 items) <7 and YMRS <7 on two 
occasions 4 weeks apart 
Mental retardation; change in psychotropic medication in past 4 weeks; DSM-IV 
alcohol/substance abuse in past 12 months; head injury with LOC; neurological 
disorder; history of psychiatric illness other than BD-I; significant physical health 
problem which could affect cognition 
Daban 
2012  
France 53 60 BD 
DSM-III-R 
MADRS <6 and BR-MRS <5  History of severe head trauma; learning difficulties; neurological disorder; 
current alcohol/drug abuse 
Doganavsargil-
Baysal 
2013  
Turkey 54 18 BD-I 
DSM-IV-TR 
H‘SD чϳ aŶd YM‘S чϱ Comorbid psychiatric or neurological disorders; IQ score <80; infectious or 
autoimmune diseases; on anti-inflammatory or antibiotic medication; 
biochemical values not within normal range 
Elshahawi 
2011  
Egypt 50 50 BD-I or BD-II; 
history of шϯ 
affective 
episodes 
ICD-10 
HRSD <8 and YMRS <6 Comorbid psychiatric disorder; ECT in past 3 months; neurological disorder; 
mental retardation; substance abuse; organic cause of cognitive impairment 
Fakhry 
2013  
UAE 30 (recent 
manic 
episode)  
30 (recent 
depressive 
episode) 
30 BD-I; history of 
чϯ affectiǀe 
episodes; illness 
duration <5 
years 
DSM-IV 
MES and MAS <6; free from symptoms for at 
least 8 weeks and not fulfilling DSM-IV 
criteria for an affective episode 
Comorbid psychiatric disorders; ECT in past 6 months; lithium-receiving patients 
in a trial  
Ferrier 
1999  
UK 21 ;͚good͛ 
outcome) 
ϮϬ ;͚poor͛ 
outcome) 
20 BD-I; at least 5 
years illness 
duration 
DSM-IV 
H‘SD чϴ aŶd MSS <ϮϬ Dementing disorder; learning disability; history of substance misuse, 
cerebrovascular disease, neurodegenerative disorders, head injury with 
concussion, clinical epilepsy, systemic illness with known cerebral 
consequences, severe hypertension, severe hepatic or renal disorder, or 
endocrine disorders other than corrected hypothyroidism 
Author 
Year 
Country Sample n BD sample type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
Frangou 
2005  
UK 44 44 BD-I 
DSM-IV 
Syndromal remission: not meeting DSM-IV 
criteria for a mood episode for at least 3 
months; no change in medication type/dose 
over the same period. Symptomatic 
remission: HRSD and MRS-SADS <10 
None  
Goswami 
2009  
India 22 (on 
medication) 
22 (not on 
medication) 
NA BD-I 
DSM-IV 
HRSD <8 and MSS <20 on two occasions 4 
weeks apart 
Other DSM Axis I or II diagnoses; cardiorespiratory, gastrointestinal, 
neurological and endocrine disorders (other than corrected hypothyroidism); 
substance misuse/dependency disorders; other medications e.g. 
anticholinergics, hypnotics or steroids 
Ibrahima 
2009  
Malaysia 40 40 BD-I 
DSM-IV 
No active manic or depressive symptoms as 
reflected by YMRS and HRSD scores 
Overtly disturbed/aggressive; severe mental retardation; dementia; significant 
CNS disease; head injury; comorbid psychiatric disorders; substance 
abuse/dependence; use of anticholinergics or benzodiazepines 
Jamrozinski 
2009  
Germany 40 40 BD-I 
DSM-IV 
MAD‘S чϭϬ aŶd YM‘S чϭϮ Other medical disorders 
Juseliusb 
2009  
Finland 26 114 BD-I 
DSM-IV (past 
diagnosis using 
ICD-8 or DSM-
III-R) 
In remission according to DSM-IV criteria Other psychotic disorders; neurological disorders; brain injury; current alcohol 
dependence 
Kieseppäb 
2005  
Finland 26 114 BD-I 
DSM-IV (past 
diagnosis using 
ICD-8 or DSM-
III-R) 
In full symptom remission according to DSM-
IV criteria 
Other psychotic disorders; neurological disorders; brain injury; current alcohol 
dependence 
Lopera-
Vásquez 
2011  
Colombia 40 (on 
medication) 
31 (not on 
medication) 
28 BD-I 
DSM-IV 
ZSDS <8 and YMRS <6 Illicit substances or benzodiazepines in past 4 weeks; other psychiatric or 
neurological disorders; mental retardation; any treatment with ECT 
López-Jaramillo 
2010  
Colombia 24 (1 manic 
episode)  
27 (2 manic 
episodes)  
ϰϳ ;шϯ ŵaŶic 
episodes) 
66 BD-I 
DSM-IV 
HRSD <8 and YMRS <6 Illicit substances or benzodiazepines in past 4 weeks; other psychiatric or 
neurological disorders that could affect cognition; mental retardation; any 
treatment with ECT; physical/sensory limitations that could affect performance 
Martinoc 
2008  
Argentina 50 30 BD-I or BD-II 
DSM-IV 
H‘SD чϴ aŶd YM‘S чϲ for at least ϲ weeks Substance abuse; mental retardation; neurological disease; any clinical 
condition that could affect cognitive performance 
Martinoc 
2011a  
Argentina 48 (BD-I)  
39 (BD-II) 
39 BD-I; BD-II 
DSM-IV 
H‘SD чϴ aŶd YM‘S чϲ for at least ϴ ǁeeks Substance abuse; mental retardation; neurological disease; any clinical 
condition that could affect cognitive performance 
Martinoc 
2011b  
Argentina 45 (BD-I)  
36 (BD-II) 
34 BD-I; BD-II 
DSM-IV 
H‘SD чϴ aŶd YM‘S чϲ for at least ϴ ǁeeks Substance abuse; mental retardation; neurological disease; any clinical 
condition that could affect cognitive performance 
Martinoc 
2011c  
Argentina 48 (BD-I)  
37 (BD-II) 
34 BD-I; BD-II 
DSM-IV 
H‘SD чϴ aŶd YM‘S чϲ for at least ϴ ǁeeks Substance abuse; mental retardation; neurological disease; any clinical 
condition that could affect cognitive performance 
Author 
Year 
Country Sample n BD sample type 
BD definition 
Euthymia definition Exclusion criteria 
  BD HC    
Martinoc 
2014  
Argentina 100 40 BD-I or BD-II 
DSM-IV 
H‘SD чϵ aŶd YM‘S чϴ for at least 8 weeks Substance abuse; mental retardation; neurological disease; any clinical 
condition that could affect cognitive performance 
Mur 
2007  
Spain 44 46 BD-I or BD-II 
DSM-IV 
HRSD (17-item) <8 and YMRS <6 for at least 3 
months; on same treatment regimen and 
clinically stable for 3 months 
Significant physical or neurologic illness; substance abuse/dependence in the 
past year; ECT in the past year; any mood-stabilising medication other than 
lithium 
Normalaa 
2010  
Malaysia 40 40 BD-I 
DSM-IV 
No active manic or depressive symptoms as 
reflected by YMRS and HRSD scores 
Overtly disturbed/aggressive; severe mental retardation; dementia; significant 
CNS disease; head injury; comorbid psychiatric disorders; substance 
abuse/dependence; use of anticholinergics or benzodiazepines 
Osher 
2011  
Israel 51 495 BD-I 
DSM-IV 
Consensus judgement by two clinicians 
based on full history and evidence of stability 
for at least three monthsd 
Serious physical illness or substance abuse  
Pirkolab 
2005  
Finland 22 100 BD-I 
DSM-III-R or 
DSM-IV 
Not stated Schizoaffective disorder; psychotic disorder other than BD-I; neurological 
disease; clinically significant head injury; mental retardation 
Sánchez-Morla 
2009  
Spain 73 67 BD 
DSM-IV 
HRSD <7 and YMRS <6 for 3 consecutive 
monthly evaluations 
Neurological or medical diseases that can affect cognition; mental retardation; 
history of alcohol or other substance abuse/dependence in past 2 years; ECT in 
past 2 years; history of head injury with LOC 
Sparding 
2015  
Sweden 64 (BD-I)  
44 (BD-II) 
86 BD-I; BD-II 
DSM-IV 
MADRS and YMRS <14 None stated 
van der Werf-
Eldering 
2010  
The 
Netherlands 
46 75 BD-I, BD-II or 
BD-NOS 
DSM-IV 
IDS-SR <14 and YMRS <8 Mental retardation; systemic or neurological disease which could affect 
cognition; alcohol use disorder currently needing treatment in a specialised 
setting 
BD, bipolar disorder; BD-I, bipolar disorder type I; BD-II, bipolar disorder type II; BD-NOS, bipolar disorder not otherwise specified; BR-MRS, Bech–Rafaelsen Mania Rating Scale; CNS, central nervous system; 
DSM, Diagnostic and Statistical Manual of Mental Disorders; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders third edition revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 
fourth edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders fourth edition text revision; ECT, electroconvulsive therapy; HC, healthy comparison; HRSD, Hamilton Rating Scale for 
Depression; ICD-8, International Classification of Diseases eighth revision; ICD-10, International Classification of Diseases tenth revision; IDS-SR, Inventory of Depressive Symptomatology - Self Rating; IQ, 
intelligence quotient; LOC, loss of consciousness; MADRS, Montgomery–Åsberg Depression Rating Scale; MAS, Bech–Rafaelsen Mania Scale; MES, Bech–Rafaelsen Melancholia Scale; MRS-SADS, Mania Rating 
Scale froŵ the Schedule for Affectiǀe Disorders aŶd SchizophreŶia ;ChaŶge VersioŶͿ; MSS, Bech͛s ŵodificatioŶ of Beigel͛s MaŶia State Rating Scale; NA, not applicable; YMRS, Young Mania Rating Scale; ZSDS, 
Zung Self-Rated Depression Scale. 
a Studies contain overlapping samples. 
b Studies contain overlapping samples. 
c Studies contain overlapping samples. 
d Information provided by author. 
Table 2 Prevalence of cognitive impairment in BD-I samples
a 
 
Author 
Year 
Sample n Cognitive measure Impairment definition Impairment prevalence n 
(%) 
d 
 BD HC   BD HC  
Altshuler 
2004  
40 22 WCST categories (executive) Score 0 to 3 (42%) (0%) -0.98 
   CVLT total recall 1-5 (verbal memory) 1.75 SD from published 
normative mean
b 
(22%) (0%) -0.99 
Cavanagh 
2002
c
  
20 20 Stroop Color-Word Test (executive) 1.64 SD from HC mean 7 (36.8%) (5%)
d
 -0.61 
   Letter fluency (executive)  2 (10%) (5%)
d
 -0.31 
   BADS Six Elements (executive)  1 (5.3%) (5%)
d
 -0.31 
   CVLT trial 1 (verbal memory)  7 (35%) (5%)
d
 -1.24 
   CVLT total recall 1-5 (verbal memory)  5 (25%) (5%)
d
 -1.06 
   CVLT delayed recall (verbal memory)  8 (42.1%) (5%)
d
 -0.96 
   CVLT delayed recognition total (verbal 
memory) 
 4 (21.1%) (5%)
d
 -0.62 
   CVLT delayed recognition minus false 
positives (verbal memory) 
 4 (21.1%) (5%)
d
 -0.66 
   Stroop Color-Word Test (executive) 2 SD from HC mean 7 (36.8%) (2.275%)
d
 -0.61 
   Letter fluency (executive)  2 (10%) (2.275%)
d
 -0.31 
   BADS Six Elements (executive)  1 (5.3%) (2.275%)
d
 -0.31 
   CVLT trial 1 (verbal memory)  2 (10%) (2.275%)
d
 -1.24 
   CVLT total recall 1-5 (verbal memory)  4 (20%) (2.275%)
d
 -1.06 
   CVLT delayed recall (verbal memory)  5 (26.3%) (2.275%)
d
 -0.96 
   CVLT delayed recognition total (verbal 
memory) 
 4 (21.1%) (2.275%)
d
 -0.62 
   CVLT delayed recognition minus false 
positives (verbal memory) 
 4 (21.1%) (2.275%)
d
 -0.66 
Cheung 
2013  
52 52 CNS-VS neurocognition (overall) 5th percentile of 
published norm 
(46.2%) (0.0%) -1.64 
   CNS-VS executive function  (53.8%) (0.0%) -1.69 
   CNS-VS cognitive flexibility  (57.7%) (0.0%) -1.66 
   CNS-VS complex attention  (51.9%) (1.9%) -1.36 
   CNS-VS processing speed  (26.9%) (0.0%) -1.21 
   CNS-VS psychomotor speed  (30.8%) (1.9%) -1.15 
   CNS-VS reaction time  (44.2%) (13.5%) -0.90 
   CNS-VS memory composite  (30.8%) (5.8%) -0.80 
   CNS-VS verbal memory  (28.8%) (5.8%) -0.71 
   CNS-VS visual memory  (11.5%) (3.8%) -0.65 
   1 SD from published normative mean 
on шϮ index scores 
 (61.5%) (1.9%) NA 
   2 SD from published normative mean 
on шϮ index scores 
 (40.4%) (0.0%) NA 
Fakhry 
2013  
S1: recent manic 
episode 
30 30 MMSE (global) Score <25 23 (76.7%) 0 (0%) -4.62 
   MTS (global) Score <27 18 (60%) 0 (0%) -2.10 
   CDT (executive/visuospatial) Score <6 0 (0%) 0 (0%) -3.31 
Fakhry 
2013  
S2: recent 
depressive 
episode 
30 30 MMSE (global) Score <25 6 (20%) 0 (0%) -2.74 
   MTS (global) Score <27 5 (16.7%) 0 (0%) -0.84 
   CDT (executive/visuospatial) Score <6 0 (0%) 0 (0%) -2.89 
Author 
Year 
Sample n Cognitive measure Impairment definition Impairment prevalence n 
(%) 
d 
 BD HC   BD HC  
Ibrahim 
2009
e
 & 
Normala 
2010
e
  
40 40 Category fluency (executive/language) Score чϯ0 3 (7.5%) 0 (0%)c -1.01 
   TMT part A (speed/attention)
c 
>40/45/50 seconds
f 
19 (47.5%) 11 (27.5%) -0.52 
   TMT part B (executive)
c 
>90/100/135 seconds
f 
25 (62.5%) 13 (32.5%) -0.81 
   Digit span forward (attention)
c 
Span <5 3 (7.5%) 1 (2.5%) -0.97 
   Digit span backward (working memory)
c 
Span <4 18 (15.0%) 5 (12.5%) -1.10 
   RAVLT trial 1 (verbal memory) Score <7 31 (77.5%) 13 (32.5%) NR 
   RAVLT trial 5 (verbal memory) Score <12 23 (57.5%) 1 (2.5%) NR 
   RAVLT trials 1 to 5 (verbal memory) Score increment <5 16 (40%) 3 (7.5%) NR 
   RAVLT list B (verbal memory) Score <7 37 (92.5%) 14 (35%) NR 
Juselius 
2009  
26
g 
114 WCST categories (executive) 1.5 SD from HC mean 12 (50%)
 
(6.68%)
d
 -0.78 
   WCST perseverative (executive)  13 (54%) (6.68%)
d
 -1.74 
   Stroop interference (executive)  15 (68%) (6.68%)
d
 -3.58 
   TMT B minus A (executive)  10 (42%) (6.68%)
d
 -0.33 
   Letter fluency (executive/language)  15 (63%) (6.68%)
d
 -1.75 
   Category fluency (executive/language)  18 (78%) (6.68%)
d
 -3.40 
Osher 
2011
c
  
51 495 Mindstreams global cognition 1.5 SD from HC mean 25 (49.0%) (6.68%)
d
 -1.19 
   Mindstreams executive function  13 (25.5%) (6.68%)
d
 -0.83 
   Mindstreams attention  20 (39.2%) (6.68%)
d
 -1.04 
   Mindstreams information processing 
speed 
 15 (29.4%) (6.68%)
d
 -0.91 
   Mindstreams memory  22 (43.1%) (6.68%)
d
 -0.96 
   Mindstreams verbal function  11 (21.6%) (6.68%)
d
 -0.51 
   Mindstreams visual-spatial  16 (31.4%) (6.68%)
d
 -0.67 
   Mindstreams motor skills  12 (23.5%) (6.68%)
d
 -0.58 
BADS, Behavioural Assessment of the Dysexecutive Syndrome; BD, bipolar disorder; BD-I, bipolar disorder type I; CDT, Clock Drawing Test; 
CNS-VS, Central Nervous System Vital Signs computerised battery; CVLT, California Verbal Learning Test; HC, healthy comparison; MMSE, Mini-
mental State Examination; MTS, Mental Test Score; NA, not applicable; NR, unable to calculate as mean and SD not reported in article; RAVLT, 
Rey Auditory Verbal Learning Test; SD, standard deviation; TMT, Trailmaking Test; WCST, Wisconsin Card Sorting Test. 
d is the standardised mean difference between BD and HC groups, calculated from unadjusted results in the article; negative values indicate 
worse performance in BD group. 
a
 Sample characteristics are reported in Supplementary Table S1. 
b
 T-score <32; impairment definition not explicit in article but inferred from bar graph of results. 
c
 Prevalence data provided by author. 
d
 By definition, according to impairment threshold applied. 
e
 Same sample; RAVLT reported in Ibrahim 2009 and other tests reported in Normala 2010. 
f
 Age groups 18-39, 40-49 and 50-59, respectively. 
g
 Sample denominator for prevalence results ranges from 22 to 24. 
Table 3 Prevalence of cognitive impairment in mixed BD samples
a 
 
Author  
Year 
Sample n 
 
Cognitive measure Impairment 
definition 
Impairment prevalence n 
(%) 
d 
 BD HC   BD HC  
Barrera 
2013
b
  
12 12 Reading the Mind in the Eyes test (theory 
of mind) 
Score <21 6 (50%) 2 (16.7%) -0.61 
   Faux Pas Recognition Test cognitive items 
(theory of mind) 
Score <0.75 7 (58.3%) 4 (33.3%) -0.77 
Daban 
2012  
53 60 WAIS-III Digit Symbol Coding (processing 
speed) 
1.64 SD from HC 
mean 
(30.2%) (5%)
c 
-0.89 
Martino 
2014  
100 40 Various tests (executive, 
attention/working memory, verbal 
memory, naming) 
1.5 SD from 
published normative 
mean in ≥ϭ cognitive 
domain  
(70%) (27.5%) NA 
    2 SD from published 
normative mean in 
≥Ϯ cognitive 
domains  
(30%) (7.5%) NA 
Mur 
2007
b
  
44 46 TMT part B (executive) 1.5 SD from 
published normative 
mean 
0 (0%) 0 (0%) -0.72 
   Letter fluency (executive/language)  6 (13.6%) 0 (0%) -0.71 
   WCST categories (executive)  18 (40.9%) 7 (15.2%) -0.87 
   WCST perseverative (executive)  15 (34.1%) 5 (10.9%) -0.49 
   Stroop inhibition (executive)  11 (25.0%) 1 (2.2%) -1.30 
   Digit span (attention/working memory)  3 (6.8%) 0 (0%) NR 
   TMT part A (speed/attention)  0 (0%) 0 (0%) -0.28 
   CVLT trial 1 (verbal memory)  11 (25.0%) 7 (15.2%) 0.19 
   CVLT total words (verbal memory)  17 (38.6%) 6 (13.0%) 0.01 
   CVLT immediate recall (verbal memory)  13 (29.5%) 4 (8.7%) 0.12 
   CVLT delayed recall (verbal memory)  12 (27.3%) 6 (13.0%) -0.33 
   RCFT immediate (visual memory)  13 (29.5%) 0 (0%) -0.52 
   RCFT delayed (visual memory)  16 (36.4%) 4 (8.7%) -0.55 
Sánchez-Morla 
2009  
73 67 Executive composite z-score 1.64 SD from HC 
mean 
33 (45.2%) (5%)
c 
-1.80 
   Sustained attention composite z-score  10 (13.7%) (5%)
c
 -0.65 
   Verbal memory composite z-score  21 (28.8%) (5%)
c
 -1.18 
   Visual memory composite z-score  24 (32.9%) (5%)
c
 -1.10 
   WCST % conceptual level response 
(executive) 
 (19.2%) (5%)
c 
-1.02 
   WCST % perseverative errors (executive)  (19.2%) (5%)
c
 -1.01 
   Stroop interference (executive)  (35.6%) (5%)
c
 -0.98 
   TMT part B (executive)  (32.9%) (5%)
c
 -0.97 
   Letter fluency (executive/language)  (16.4%) (5%)
c 
-1.00 
   Animal fluency (executive/language)  (24.7%) (5%)
c
 -0.89 
   Tower of Hanoi no. of movements 
(executive) 
 (19.0%) (5%)
c
 -0.64 
   Digit span backward (working memory)  (11.0%) (5%)
c
 -0.53 
   CPT hits (attention)   (9.6%) (5%)
c 
-0.52 
   CPT sensitivity A (attention)  (9.6%) (5%)
c
 -0.58 
   CPT reaction time (attention/speed)  (23.3%) (5%)
c
 -0.72 
   CVLT total recall 1-5 (verbal memory)  (19.2%) (5%)
c
 -0.97 
   CVLT short free-recall (verbal memory)  (27.4%) (5%)
c 
-0.96 
   CVLT long free-recall (verbal memory)  (15.1%) (5%)
c
 -0.97 
   CVLT short cued-recall (verbal memory)  (20.5%) (5%)
c
 -1.11 
   CVLT long cued-recall (verbal memory)  (23.3%) (5%)
c
 -0.97 
Author  
Year 
Sample n 
 
Cognitive measure Impairment 
definition 
Impairment prevalence n 
(%) 
d 
 BD HC   BD HC  
   CVLT recognition discriminability (verbal 
memory) 
 (8.2%) (5%)
c 
-0.67 
   CVLT semantic strategies trial A (verbal 
memory) 
 (41.1%) (5%)
c
 -0.82 
   RCFT copy (visuospatial)  (16.4%) (5%)
c
 -0.51 
   RCFT short-term (visual memory)  (31.5%) (5%)
c
 -0.98 
   RCFT long-term (visual memory)  (32.9%) (5%)
c
 -1.01 
van der Werf-
Eldering 
2010  
46 75 Various tests (executive, 
attention/working memory, reaction 
time, verbal and visual memory) 
2 SD from HC mean 
in ≥ϭ cognitive 
domain 
6 (13%) (2.275%)
c 
NA 
BD, bipolar disorder; BD-I, bipolar disorder type I; CPT, Continuous Performance Test; CVLT, California Verbal Learning Test; HC, healthy 
comparison; NA, not applicable; NR, unable to calculate as mean and SD not reported in article; RCFT, Rey Complex Figure Test; SD, standard 
deviation; TMT, Trailmaking Test; WAIS-III, Wechsler Adult Intelligence Scale third edition; WCST, Wisconsin Card Sorting Test. 
d is the standardised mean difference between BD and HC groups, calculated from unadjusted results in the article; negative values indicate 
worse performance in BD group. 
a
 Sample characteristics are reported in Supplementary Table S2. 
b
 Prevalence data provided by author. 
c
 By definition, according to impairment threshold applied. 





  
Appendix 1 Search strategy implemented in Web of Science 
 
Search set-up: English; publication year 1994 to date 
 
1 TS=((bipolar NEAR/3 depress*) OR (bipolar NEAR/3 disorder*) OR (manic NEAR/0 depress*)) 
2 TS=(cogniti* OR neuro-cogniti* OR neurocogniti* OR neuro-psycholog* OR neuropsycholog* OR 
speed OR reaction OR attention OR memory OR learning OR *spatial OR executive OR reasoning 
OR IQ OR intelligence) 
3 TS=(impair* OR dysfunction* OR declin* OR deteriorat* OR defici*) 
4 (#1 AND #2 AND #3) 
5 TI=(therapy OR CBT OR cognitive-behavio* OR (cognitive NEAR/0 behavio*)) 
6 #4 NOT #5 
7 TS=((nursing NEAR/0 home*) OR (care NEAR/0 home*)) 
8 #6 NOT #7 
9 TS=(dement*) 
10 #8 NOT #9 
 
Results limits: Refined by: Databases: ( WOS OR SCIELO OR MEDLINE OR CCC OR DRCI ) AND 
DOCUMENT TYPES: ( ARTICLE OR CLINICAL TRIAL OR DATA SET OR UNSPECIFIED OR OTHER OR DATA 
STUDY ) AND LANGUAGES: ( ENGLISH ) 
 
  
Appendix 2 Eligibility checklist used when screening titles, abstracts and full text 
 
No. Criteria and definitions 
1 Original research published in peer-reviewed journals, from 1994 until date of search 
 Not editorials, opinion papers, reviews, meta-aŶalǇses ;ďut ͚iŶdiǀidual patieŶt data ŵeta/ŵega-
aŶalǇses͛ that iŶǀolǀe re-analysis of raw data [rather than group effect sizes] are acceptable) 
 Not conference proceedings, books, book chapters, academic theses 
 Not single case studies or case series (must be group studies) 
 If unsure whether journal is peer-reviewed, check the journal website or look up the title at 
https://ulrichsweb.serialssolutions.com/ aŶd look for the ͚refereed͛ sǇŵďol:  
 Publication year is 1994 or later 
2 Articles published in English 
 Full text of the article must be available in English 
3 Studies of community-dwelling adults aged 18 to 70 years inclusive 
 Out-patient service or general population setting (this refers to the setting in which participants 
were recruited and/or the study took place) 
 BD participants may be recruited from clinic attendees, or from a population study (e.g. large-
scale population registry) 
 Participants must have been living in the community at time of assessment 
 Not currently a hospital in-patient (but hospital/clinic out-patient is acceptable) 
 Not living in a nursing/care home 
 Participants are adults of minimum age 18 years and maximum age 70 years (abstracts 
desĐriďiŶg saŵples as ͚adolesĐeŶt͛ or ͚elderlǇ͛ are presuŵed to ďe iŶeligiďle uŶless theǇ also 
ŵeŶtioŶ a separate saŵple of ͚adults͛ iŶ the studǇͿ 
 There may be a healthy comparison group in the study, but this is not a requirement 
4 Cross-sectional study design 
 The key criterion is that the assessment of mood disorder status (whether the person has 
euthymic BD – the ͚eǆposure͛Ϳ aŶd the assessŵeŶt of ĐogŶitiǀe perforŵaŶĐe ;the ͚outĐoŵe͛Ϳ 
took place at the same time (maximum allowable time gap between establishing euthymic status 
and carrying out cognitive assessment = 2 weeks) 
 The mood disorder may have been diagnosed in the past; this is acceptable (as long as the 
confirmation of current euthymic status took place at the same time as the cognitive assessment 
– see section 8 below) 
 A cross-sectional study of this type may be part of a prospective/longitudinal/cohort study or a 
treatment trial; this is acceptable as long as separate (standalone) results are presented for the 
cross-sectional component that we are interested in 
 Studies investigating whether cognitive status predicts future remission of mood disorder are not 
eligible 
5 If clinical out-patient service setting, samples must be consecutively recruited 
 Where BD participants have been recruited via a clinical service, recruitment must have been 
consecutive and representative of the target group 
 This means participants should not have been selectively approached (e.g. on the basis of their 
cognitive function or some other characteristic) in a way that might bias the results of the study 
 All eligible patients in the target group should have had an equal chance of being approached 
 For example, if the target group was patients with euthymic BD, and the researchers considered 
all such patients attending the clinic between time X and time Y (or a randomly chosen subset of 
these), then that would be acceptable 
6 Primary diagnosis of bipolar disorder (BD) 
 Primary means the disorder has been diagnosed in its own right, not secondary to another illness 
 BD = History of bipolar disorder (type I or II or unspecified), meeting DSM or ICD criteria 
 Evidence for meeting diagnostic criteria may come from direct assessment as part of the study 
(often including a semi-struĐtured iŶterǀieǁ sĐheduleͿ, or froŵ a doĐtor͛s diagŶosis reĐorded iŶ 
the medical notes 
 Questionnaire measures of mood state alone (without reference to a diagnostic reference 
system) are not acceptable 
 The diagŶosis ŵaǇ haǀe ďeeŶ ŵade at aŶǇ tiŵe iŶ the persoŶ͛s life up uŶtil the tiŵe of the studǇ 
7 Euthymic at time of assessment 
 Not meeting DSM or ICD criteria for a depressive or manic episode at time of cognitive 
  
assessment; or as otherwise defined by the study authors based on an appropriate clinical 
measure 
 For example, the authors may define euthymia as being below X threshold on a depression or 
mania rating scale 
 The concept of euthymia may be referred to as remitted/remission, or recovery, or stable on 
treatment, or treatment-responsive (or other similar phrase) 
 Non-euthymic patients may be described as acutely manic/unwell, or treatment-resistant (or 
other similar phrase) 
 Baseline samples within treatment trial studies are presumed to be NOT euthymic unless the 
abstract says otherwise 
8 Assessed using at least one standardised cognitive measure 
 The measure should be an objectiǀe test, oŶ ǁhiĐh the partiĐipaŶt͛s perforŵaŶĐe is assessed 
directly 
 Self-report questionnaires are not acceptable (e.g. the participant rates how good they think 
their cognition is) 
 Informant-rated questionnaires are not acceptable (e.g. the participant͛s spouse rates hoǁ good 
theǇ thiŶk the partiĐipaŶt͛s ĐogŶitioŶ isͿ 
 Informal behavioural observations are not acceptable (e.g. researcher observes participant 
without using any standardised rating scale) 
 The cognitive test may cover one or more of the following abilities/domains: 
o Global/overall function (cognitive/neuropsychological)  
o Processing speed/psychomotor speed/reaction time 
o Attention/vigilance/alertness/concentration 
o Working memory/memory/learning/encoding/recall/recognition/retrieval 
o Spatial/visuospatial ability 
o Language/naming/comprehension  
o Executive function (including planning, strategy-formation, problem-solving, decision-
making, initiation, self-monitoring, self-regulation, mental control, goal management, 
goal neglect, inhibition, response suppression, fluency, word generation, perseveration, 
set-shifting, rule-shifting, flexibility, impulsivity, sequencing, dual-tasking, multi-tasking) 
o Reasoning/abstraction/concept formation/IQ/intelligence 
o Social cognition (including theory of mind, meta-cognition – e.g. judgement of other 
people͛s thoughts/ďehaǀioursͿ 
 Studies of non-conscious learning (e.g. classical conditioning and extinction) are not eligible 
 Studies using only experimental neuroimaging tasks (e.g. oddball/continuous performance tasks 
that are not interpretable in their own right) are not eligible 
 Studies of basic emotional processing only, without an explicit social cognition aspect, (e.g. 
reaction times to emotional faces) are not eligible 
 The test should yield a numeric score, or a rating (e.g. pass/fail, or poor/fair/good, or 
impaired/unimpaired) 
 NOTE: The mood disorder literature also contains many studies about cognitive 
distortions/biases. For example, a study may look at biased thinking patterns, attitudes, or 
rumination. This can be thought of as cognitive style, which is not the same as cognitive function 
in the neuropsychological sense outlined above. Therefore studies which are solely about these 
cognitive distortions, including treatments such as CBT aimed at changing these distortions, are 
not relevant to this review.  
 Similarly, some studies may focus on formal thought disorder (e.g. tangentiality, flight of ideas); 
these are not eligible unless a cognitive assessment of the type outlined above is also conducted. 
9 Samples NOT selected on the basis of presence of cognitive impairment (known or suspected) 
 Participants (BD participants, or healthy comparison participants) should have been recruited 
(approached/selected) based on their exposure status (having or not having BD), and NOT based 
on their outcome status (having or not having cognitive impairment) 
 It is possible that potential participants who were approached to take part might have been 
ŵore or less likelǇ to agree depeŶdiŶg oŶ their ĐogŶitiǀe status; this is outside the researĐher͛s 
control and so is not the focus here. Rather, the issue is that the initial approach/selection by the 
researcher should not be based on cognitive status 
 
  
Appendix 3 Instructions for data extraction  
 
Spreadsheet 
field no. 
Description Entry format 
1  Publication ID  Number 
2  Sub-ID (use if study contains separate results for >1 
BD sample) 
Number-letter 
3  Authors (e.g. Bloggs, A.B., Jones, C.D. & Smith, E.F.)  Free text 
4  Year  XXXX 
5  Journal Free text 
6  Volume  Free text 
7  Pages   XX-YY 
8  Title Free text 
9  CorrespoŶdiŶg author’s Ŷaŵe aŶd eŵail  Free text 
10  Study funding source  Free text or Not stated 
11  Any other conflicts of interest declared  Free text or Not stated 
12  Study setting: type 1=general community (e.g. population cohort) 
2=clinical service 
3=other 
4=not stated 
13  Study setting: details Free text or Not stated 
14  Population from which BD sample was drawn (e.g. 
all BD patients known to clinical service between 
date X and date Y; all families with 2 or more BD 
patients, etc)  
Free text or Not stated 
15  Healthy comparison group included 1=none (no healthy controls) 
2=internal (from same population e.g. BD and 
controls taken from same general pop cohort) 
3=external (from different population e.g. BD from 
clinic and controls from posters in community) 
16  Comparison group matching  
(NB this refers to planned matching during 
recruitment – i.e. matched study design - not 
whether some characteristics happened to be 
similar after analysis) 
1=not matched 
2=matched to BD at group level only (unpaired 
design) 
3=matched to BD individually (paired design) 
4=NA 
5=not stated 
17  Comparison group: characteristics matched by  Free text or NA or Not stated 
18  Recruitment procedure for BD group Free text or Not stated 
19  Recruitment procedure for comparison group  Free text or NA or Not stated 
20  Inclusion criteria for BD group Free text or Not stated 
21  Exclusion criteria for BD group Free text or Not stated 
22  Inclusion criteria for comparison group Free text or NA or Not stated 
23  Exclusion criteria for comparison group Free text or NA or Not stated 
24  Informed consent obtained from all participants  1=yes 
2=no 
3=not stated 
25  Power/sample size calculation reported for the 
study  
1=yes 
2=no 
26  Country where study took place Free text or Not stated 
27  Language in which cognitive test was administered 
(assume English if test name and citation are for 
English version AND study is from English-speaking 
country) 
Free text or Not stated 
28  BD sample: sample size n or Not stated 
29  BD sample: age (mean and SD, or median and IQR, 
or range) 
Free text or Not stated 
30  BD sample: sex (n and % male) Free text or Not stated 
31  BD sample: ethnicity (n and % in each category) Free text or Not stated 
  
32  BD sample: education (info re years or 
qualifications) 
Free text or Not stated 
33  BD sample: socioeconomic status (how measured, 
and status of sample) 
Free text or Not stated 
34  Comparison sample: sample size n or NA or Not stated 
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and IQR, or range) 
Free text or NA or Not stated 
36  Comparison sample: sex (n and % male) Free text or NA or Not stated 
37  Comparison sample: ethnicity (n and % in each 
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Free text or NA or Not stated 
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39  Comparison sample: socioeconomic status (how 
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Free text or NA or Not stated 
40  Qualifications/training of person who made BD 
diagnosis  
Free text or Not stated 
41  Qualifications/training of person who did cognitive 
assessment  
Free text or Not stated 
42  BD definition (e.g. DSM IV/ICD-10 criteria) Free text or Not stated 
43  Euthymia definition (e.g. score less than X on 
named questionnaire, or clinician judgement of 
remission, etc)  
Free text or Not stated 
44  Euthymia confirmed at time of cognitive 
assessment 
1=yes 
2=no 
3=not stated 
45  Age at onset of BD (mean and SD, or median and 
IQR, or range)  
Free text or Not stated 
46  Duration since onset of BD (mean and SD, or 
median and IQR, or range) 
Free text or Not stated 
47  Number of previous illness episodes, all types 
combined (mean and SD, or median and IQR, or 
range)  
Free text or Not stated 
48  Number of previous depressive episodes (mean 
and SD, or median and IQR, or range)  
Free text or Not stated 
49  Number of previous manic/hypomanic episodes 
(mean and SD, or median and IQR, or range)  
Free text or Not stated 
50  Number of previous mixed episodes (mean and SD, 
or median and IQR, or range)  
Free text or Not stated 
51  BD sample: n and % currently taking any 
psychotropic medication 
Free text or Not stated 
52  BD sample: further details of medication type and 
dosage 
Free text or Not stated 
53  Comparison sample: n and % currently taking any 
psychotropic medication 
Free text or NA or Not stated 
54  Comparison sample: further details of medication 
type and dosage 
Free text or NA or Not stated 
55  Cognitive assessment: name of test   Free text 
56  Cognitive assessment: source reference (journal 
citation; or name of publishing company)   
Free text or Not stated 
57  Cognitive assessment: domain covered (e.g. verbal 
memory)  
Free text or Not stated 
58  Cognitive assessment: definition of impairment 
threshold (e.g. 2SD below control mean score on 
one test; or 2SD below control mean score on at 
least two tests; or 1.5SD below published norms; 
or scores less than X; etc) 
Free text or Not stated 
59  Prevalence of cognitive impairment in BD sample 
(n and % who meet the stated definition of 
impairment given in field 58) 
Free text or Not stated 
  
 
* Optional fields – only complete these for papers for which information is available regarding prevalence of impairment (fields 
59 and 60), otherwise enter NA 
60  Prevalence of cognitive impairment in comparison 
sample (n and % who meet the stated definition of 
impairment given in field 58) 
Free text or NA or Not stated 
61  Source of prevalence info (or explanation for 
missing info) 
1=provided in paper 
2=author provided on request 
3=info missing: author replied but did not provide 
4=info missing: author did not reply 
62  Statistical analysis method to test/adjust for 
confounders/covariates (e.g. multiple regression)  
Free text or NA or Not stated 
63  Confounders/covariates (apart from other 
cognitive measures) that were significantly 
associated with cognitive performance in the 
analysis (e.g. higher age was a significant 
independent predictor of worse performance)  
Free text or NA or Not stated 
64  Missing data: brief description of level of missing 
data in the analysis (e.g. 10% of BD patients were 
missing a memory score)  
Free text or Not stated 
65  Missing data: brief description of how authors 
dealt with missing data (e.g. complete case 
analysis, or all available data, or imputation)  
Free text or Not stated 
66  Any other comments  Free text 
67 * Group cognitive score: BD sample (unadjusted 
group average) (mean and SD, or median and IQR, 
or range) 
Free text or NA or Not stated 
68 * Group cognitive score: comparison sample 
(unadjusted group average) (mean and SD, or 
median and IQR, or range) 
Free text or NA or Not stated 
69 * CoheŶ’s d (if M and SD available in fields 67 and 
68). Minus sign = BD worse; calculate using 
http://www.uccs.edu/~lbecker/  
Free text or NA or Not stated 
70  Full list of all confounders/covariates tested (apart 
from other cognitive measures), whether 
significant or not (additional info for field 63) 
Free text or NA or Not stated 
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Table S1 Characteristics of BD-I samples 
 
Author 
Year 
Age (years),  
M (SD) 
Male gender,  
n (%) 
Education (years),  
M (SD) 
BD onset 
age and/or 
duration 
(years),  
M (SD) 
BD past 
illness 
episodes,  
M (SD) 
Psychotropic medication 
in BD sample 
 BD HC BD HC BD HC    
Altshuler 
2004  
49.9 
(13.9) 
51.8 
(12.6) 
40 
(100%) 
22 
(100%) 
15.5 (2.4) 14.9 (2.0) Onset  
26.7 (9.2) 
Duration  
24.9 (11.1) 
Not stated Lithium 63%, 
anticonvulsant 30%, 
antidepressant 10%, 
benzodiazepine 8%, 
typical antipsychotic 
15%, anticholinergic 5% 
Cavanagh 
2002  
43.6 
(14.2) 
42.2 
(14.7) 
10 
(50%) 
10 
(50%) 
Not stated Not stated Duration  
16 (12.5) 
Depressive  
6 (6) 
Manic  
6 (7) 
SSRI 35%, typical 
antipsychotic 40%, 
lithium 40%, 
carbamazepine 25% 
Cheung 
2013  
38.57 
(10.70) 
37.76 
(10.27) 
19 
(36.5%) 
19 
(36.5%) 
12.0 (2.94) 14.04 (3.11) Onset  
24.63 (7.6) 
Duration  
13.3 (8.3) 
Depressive 
5.1 (5.2) 
Manic  
5.2 (5.0) 
Monotherapy (sodium 
valproate, lithium, 
antipsychotic, 
carbamazepine or 
lamotrigine) 48.1%, 
combination therapy 
48.1% (inc. 
anticholinergic 15.3%); 
Two patients received 
short-acting low-dose 
benzodiazepine 12h 
before assessment 
Fakhry 
2013  
S1: recent 
manic 
episode 
32.27 
(7.43) 
31.47 
(5.93) 
17 
(56.7%) 
15 
(50%) 
Middle 
3 (10%)  
Secondary 
12 (40%) 
University 
15 (50%) 
Middle  
3 (10%) 
Secondary 
12 (40%) 
University 
15 (50%) 
Not stated Not stated Antipsychotic n=30, 
mood stabiliser other 
than lithium n=28 
Fakhry 
2013  
S2: recent 
depressive 
episode 
31.60 
(6.43) 
As 
above 
13 
(43.3%) 
As 
above 
Middle 
3 (10%) 
Secondary 
15 (50%) 
University 
12 (40%) 
As above Not stated Not stated Antipsychotic n=28, 
mood stabiliser other 
than lithium n=26, 
antidepressant n=22 
Ibrahim 
2009
a
 & 
Normala 
2010
a
  
Mdn 
37.5 
IQR 
20.0 
Mdn 
27.0 
IQR 
15.0 
19 
(47.5%) 
10 
(25%) 
Not stated Not stated Onset  
Mdn 21 
IQR 13 
Duration  
10.95 (9.04) 
All types  
3.83 (3.07) 
Mood stabiliser only 
27.5%, mood stabiliser + 
antipsychotic 55%, mood 
stabiliser + 
antidepressant 2.5%, 
antipsychotic only 15% 
Juselius 
2009
b
  
 
44.2 
(1.6) 
47.8 
(0.6) 
15 
(57.7%) 
55 
(48.2%) 
Level 
attained
c
 
4.1 (0.5) 
Level 
attained
c
  
4.1 (0.2)  
Duration  
20.5 (5.8) 
Manic  
3.8 (0.45) 
Not stated 
Osher 
2011  
41.3 
(13.2) 
53.7 
(18.9) 
25 
(49%) 
181 
(37%) 
12.8 (2.0) 15.3 (3.2) Onset 
24.0 (8.0) 
Not stated Mood stabiliser 
monotherapy n=12, 
neuroleptic 
monotherapy n=8, 
polytherapy n=31 
BD, bipolar disorder; BD-I, bipolar disorder type I; HC, healthy comparison; M, mean; Mdn, median; IQR, interquartile range; SD, standard 
deviation; SSRI, selective serotonin reuptake inhibitor.  
a
 Same sample. 
b
 All participants were twins. BD sample (n=26) included 20 individuals whose co-twin did not have BD plus 3 pairs (6 individuals) concordant 
for BD. HC sample included n=114 twins (46 pairs + 22 individuals) with no history of BD in the participant or their co-twin. 
c
 Level 4 is "vocation school or equivalent", after graduating high school. 
Table S2 Characteristics of mixed BD samples 
 
Author  
Year 
% 
with 
BD-I 
Age (years),  
M (SD) 
Male gender,  
n (%) 
Education (years),  
M (SD) 
BD onset 
age and/or 
duration 
(years),  
M (SD) 
BD past 
illness 
episodes,  
M (SD) 
Psychotropic 
medication in BD 
sample 
  BD HC BD HC BD HC    
Barrera 
2013  
58% 48.21 
(11.24) 
46.04 
(12.30) 
12 
(100%) 
12 
(100%) 
12.33 
(2.67) 
12.50 
(2.71) 
Onset  
25 (7.93) 
Depressive  
10.63 (13.5) 
Manic  
5 (3.8) 
Mood stabiliser 
83.3%, 
antipsychotic 
50%, anxiolytic 
30% 
Daban 
2012  
Not 
stated 
41.12 
(10.87) 
46.53 
(13.99) 
23 
(43.4%) 
20 
(33.3%) 
14.21 
(3.05) 
12.49 
(2.75) 
Not stated Not stated Not stated 
Martino 
2014  
51% 39.55 
(10.83) 
40.28 
(12.03) 
36 
(36%) 
12 
(30%) 
14.36 
(2.36) 
13.88 
(2.77) 
Onset  
27.65 (9.49) 
Duration  
11.18 (6.67) 
Depressive  
3.46 (2.01) 
Manic  
3.18 (2.09) 
Mood stabiliser 
100%, 
antidepressant 
38%, 
benzodiazepine 
55%, 
antipsychotic 
55%  
Mur 
2007  
Not 
stated 
42.6 
(13.0) 
42.2 
(12.4) 
22 
(50%) 
23 
(50%) 
10.5 
(3.2) 
12.5 (3.4) Onset 
25.6 (11.5) 
Duration 
16.9 (11.67) 
Manic 
2.45 (2.5) 
Lithium 
monotherapy 
n=20, lithium 
plus other n=24 
Sánchez-
Morla 
2009  
75% 43.5 
(10.4) 
43.8 
(11.2) 
30 
(41.1%) 
31 
(46.3%) 
12.5  
(3.9) 
14.1  
(3.5) 
Onset  
26.2 (9.3) 
Duration  
17.3 (10.5) 
All types  
13.3 (11.2) 
Manic  
6.0 (5.6) 
Lithium 39.8%, 
anticonvulsant 
26.0%, lithium + 
anticonvulsant 
30.1%, SSRI 
30.1%, 
benzodiazepine 
23.3%, typical 
antipsychotic 
8.2%, atypical 
antipsychotic 
26.0% 
van der 
Werf-
Eldering 
2010  
83% Not 
stated
a 
40.8 
(14.4) 
Not 
stated
a 
27 
(36%) 
Not 
stated
a 
Level 
attained
b 
3.7 (1.1)  
Not stated
a 
Not stated
a 
Not stated
a 
BD, bipolar disorder; HC, healthy comparison; M, mean; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor.  
a
 This information not reported in article for euthymic group separately. 
b
 Ranging from 1 = primary school to 6 = PhD or higher degree obtained. 
 
Table S3 Prevalence of cognitive impairment in BD-I versus BD-II samples, from Sparding et al. (2015)
 
 
Cognitive measure Impairment 
prevalence
a,b
 
 BD-I
c 
BD-II
d 
D-KEFS TMT 2 number sequencing (executive/speed) 34% 19% 
D-KEFS TMT 3 letter sequencing (executive/speed) 22% 14% 
D-KEFS TMT 4 number-letter switching (executive) 48% 43% 
D-KEFS Verbal Fluency 2 category (executive/language) 38% 39% 
D-KEFS Verbal Fluency 3 category switching total (executive/language) 34% 27% 
D-KEFS Verbal Fluency 3-v category switching accuracy (executive) 18% 11% 
D-KEFS Color-Word 3 inhibition (executive) 29% 29% 
D-KEFS Color-Word 4 inhibition/switching (executive) 27% 15% 
D-KEFS Design Fluency 3 switching (executive) 32% 17% 
D-KEFS Tower rule violations (executive) 34% Not stated 
WAIS-III Matrix Reasoning (abstract reasoning) 21% 30% 
WAIS-III Similarities (abstract reasoning) 13% 11% 
WAIS-III Letter-Number Sequencing (working memory) 22% 28% 
WAIS-III Arithmetic (working memory) 37% 31% 
WAIS-III Symbol Search (speed) 28% 19% 
WAIS-III Digit-Symbol Coding (speed) 19% 11% 
WAIS-III Digit Symbol Coding copy (speed) 35% 19% 
WAIS-III Block Design (speed/visuospatial) 40% 44% 
RCFT time to copy (speed/visuospatial) 23% 24% 
RCFT 3-minute recall (visual memory) 23% 21% 
RCFT recognition (visual memory) 22% 21% 
WAIS-III Digit Symbol Coding free recall (visual memory) 25% 16% 
WAIS-III Digit Symbol Coding pairing (visual memory) 26% 27% 
WAIS-III Picture Completion (visuospatial) 14% 16% 
BD-I, bipolar disorder type I; BD-II, bipolar disorder type II; D-KEFS, Delis-Kaplan Executive Function System; HC, healthy comparison; RCFT, Rey 
Complex Figure Test; SD, standard deviation; TMT, Trailmaking Test; WAIS-III, Wechsler Adult Intelligence Scale third edition. 
a
 Impairment threshold is 1.25 SD from HC mean; HC impairment prevalence is 10.57% by definition. HC sample (n=86) was frequency 
matched to BD samples based on age, gender and years of education; details not reported in article. 
b
 Standardised mean difference between BD and HC groups is not given in table because SD was not reported in article. 
c
 BD-I (n=64) sample characteristics: age M=38 (SD=14); 48% male; education level M=3.7 (SD=1.1) (where 3=12 years, 4=13–15 years); age of 
onset M=19 (SD=9); past illness episodes (all types) M=19 (SD=26); medications: lithium 68%, antipsychotic 32%, antidepressant 31%, 
anticonvulsant 32%. 
d
 BD-II (n=44) sample characteristics: age M=35 (SD=12); 45% male; education level M=3.9 (SD=1.2) (where 3=12 years, 4=13–15 years); age of 
onset M=18 (SD=11); past illness episodes (all types) M=18 (SD=18); medications: lithium 48%, antipsychotic 11%, antidepressant 41%, 
anticonvulsant 32%. 
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Altshuler 
2004 
N Y N Y ? Y ? Y Y Y 
Arslan 
2014 
N Y N Y ? Y Y Y Y Y 
Barrera 
2013 
N Y N N ? Y ? ? Y NA 
Cavanagh 
2002 
Y Y N Y Y Y Y ? Y NA 
Cheung 
2013 
N Y Y Y ? Y Y Y Y Y 
Daban 
2012 
Y Y Y N ? Y ? Y Y Y 
Doganavsargil-Baysal 
2013 
N Y N N ? Y ? Y Y Y 
Elshahawi 
2011 
Y Y Y Y ? Y ? Y Y Y 
Fakhry 
2013 
Y Y N Y ? Y ? Y Y Y 
Ferrier 
1999 
N Y N Y ? Y ? Y Y Y 
Frangou 
2005 
Y Y N Y ? Y Y Y Y NA 
Goswami 
2009 
Y Y N N ? Y Y Y Y Y 
Ibrahim
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2009 
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2009 
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2009 
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2011a 
Y Y N Y ? Y Y Y Y Y 
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c 
2011b 
Y Y N Y ? Y Y Y Y Y 
Martino
c 
2011c 
Y Y N Y ? Y Y Y Y Y 
Martino
c 
2014 
N Y Y Y ? Y Y Y Y Y 
Mur 
2007 
Y Y N Y ? Y Y Y Y Y 
Normala
a 
2010 
Y Y N Y ? Y Y Y Y Y 
Osher 
2011 
Y Y Y Y ? Y Y Y Y Y 
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Figure S1 Ratings of risk of bias using Munn et al. critical appraisal tool for systematic reviews 
addressing questions of prevalence  
 
a
 Studies contain overlapping samples. 
b
 Studies contain overlapping samples. 
c
 Studies contain overlapping samples. 
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Figure S2 Ratings of reporting bias using STROBE checklist for cross-sectional studies 
 
a
 Rated Yes if information reported for bipolar disorder sample, at a minimum. 
b
 Studies contain overlapping samples. 
c
 Studies contain overlapping samples. 
d
 Studies contain overlapping samples. 
 
 
Y Yes 
N No 
NA Not applicable 
 
  
 
 
 
 
Figure S3 Funnel plots with pseudo 95% confidence limits
 
 
SE, standard error. 
Plots show cognitive impairment prevalence estimates and standard errors by cognitive domain, using results reported at 
the 5
th
 percentile impairment threshold. Standard errors were calculated as follows: sqrt((prevalence*(100-
prevalence))/n). Some studies contributed more than one data point to the plot; data points are labelled by study.  
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Figure S4 Variables associated with cognitive impairment 
 
ADHD, attention deficit hyperactivity disorder; BD, bipolar disorder; F, female; M, male. 
a
 Analysis based on number of recent episodes as well as time to recovery. 
b
 Studies contain overlapping samples. 
c
 Positive association with cognitive performance on some scores. 
d
 Studies contain overlapping samples. 
e
 Studies contain overlapping samples. 
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